



Screen-ERR™

A NEW Service offered by Med-E.R.R.S.®

Introduction

Med-E.R.R.S.® has launched a new service called Screen-ERR™. Screen-ERR™ is designed to help companies evaluate multiple pharmaceutical trademark candidates at an early stage in the trademark development process. It is offered by Med-E.R.R.S. as a service that is used to determine whether any regulatory or other concerns exist which may result in a name not being acceptable to regulatory health authorities. Screen-ERR™ should be used as a tool to help eliminate unacceptable trademark candidates from the list of proposed trademark candidates at an early stage.

The services offered under Screen-ERR™ are not intended to replace or supercede the Med-E.R.R.S. name safety testing process (the ERRS MODEL™), as the Screen-ERR™ program does not test for handwritten or verbal confusability of trademarks.

Uses

Screen-ERR™ ideally should be used after preliminary legal screening has taken place. The client should provide any clinical information (if available) about the product including, but not limited to, therapeutic class of drugs, intended indication(s), route of administration, and non-proprietary name, as well as in which countries the trademarks are intended to be used. This information may be helpful in determining acceptability of the potential trademarks as it relates to the criteria being screened.

Report

A report will be generated that will contain an overview of the methods used for this screening process as well as tables containing the trademark candidates. Each trademark candidate will be given a rating reflecting its acceptability. For those with an unacceptable or questionable rating, the reason for this rating will be explained.

“Working with the pharmaceutical industry to prevent medication errors”



Med-E.R.R.S.
1800 Byberry Road, Suite 808
Huntingdon Valley, PA 19006, USA

Details of Screen-ERR™ Service

Under the Screen-ERR™ service, trademark candidates are reviewed within the following areas:

- Stems (i.e., prefix, suffix or infix) as they relate to USAN and/or INN;
- Regulatory issues at FDA and/or EMEA (primarily those that involve DDMAC [Division of Drug Marketing, Advertising and Communication] or equivalent groups within other health authorities);
- Internet-based resources;
- Selected drug information references; and
- General opinion of the trademark candidates by Med-E.R.R.S expert staff.

